By Fineline Cube Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced the completion of its acquisition of Kira Pharmaceuticals through an all-stock transaction. The combined company will continue trading on Nasdaq under the ticker symbol “JSPR” and has simultaneously secured a $132 million private placement financing to advance Kira’s complement therapies pipeline for immune-mediated diseases.
Transaction Details
| Component | Detail |
|---|---|
| Acquisition Type | All-stock transaction |
| Target Company | Kira Pharmaceuticals |
| Ticker Symbol | JSPR (unchanged) |
| Financing | $132 million private placement |
| Shares Issued | 4.7 million shares of non-voting convertible preferred stock |
| Closing Date | Expected July 20, 2026 |
| Conversion Terms | Each preferred share converts to 61 common shares upon stockholder approval |
Investor Consortium
- Lead Investors: Affinity Asset Advisors, LLC and Ikarian Capital LLC
- Participating Institutions: Columbia Threadneedle Investments, Sirenia Capital Management LP, Brahma Capital, Balyasny Asset Management, SilverArc Capital, Squadron Capital Management, Nazare Partners LP, Mirador Therapeutics
- Additional Participants: Certain members of Kira’s management team
- Strategic Alignment: Strong backing from leading life sciences investors with expertise in immunology and rare disease therapeutics
Kira Pharmaceuticals Pipeline Overview
| Asset | Stage | Mechanism | Key Indications |
|---|---|---|---|
| KP-104 (Vensobafusp alfa) | Clinical | First-in-class dual-target complement therapeutic | IgA nephropathy, C3 glomerulopathy, SLE-TMA, PNH |
| Briquilimab | Late-stage | Anti-KIT antibody with best-in-class potential | Immune-mediated disorders |
| KP-701 | Preclinical | B-cell receptor targeting therapy | Autoimmune conditions |
| Out-licensed Assets | — | KP-301 (anti-C5a mAb), KP-402 (C5aR antagonist) | Licensed to Mirador Therapeutics |
Strategic Rationale & Market Opportunity
- Therapeutic Focus: Immune-mediated diseases represent a $150+ billion global market with significant unmet medical needs
- Pipeline Synergy: Kira’s complement-focused pipeline complements Jasper’s existing hematopoietic cell transplant platform
- Clinical Differentiation: KP-104’s dual-target mechanism offers potential advantages over single-target complement inhibitors currently on the market
- Financial Position: The $132 million financing provides runway through multiple Phase III readouts and potential commercial launch preparations
Competitive Landscape Analysis
- Complement Inhibition Market: Currently dominated by Alexion’s Soliris and Ultomiris, with emerging competition from Apellis and others
- KP-104 Advantage: Dual-target approach may address limitations of current anti-C5 therapies in specific patient populations
- Market Timing: Increasing regulatory acceptance of complement-targeted therapies creates favorable environment for pipeline advancement
Forward‑Looking Statements
This brief contains forward-looking statements regarding the acquisition, financing, clinical development timelines, and market opportunities. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, integration challenges, and competitive dynamics in the biopharmaceutical industry.-Fineline Info & Tech